Formulation and ex vivo–in vivo evaluation of pH-triggered brimonidine tartrate in situ gel for the glaucoma treatment using application of 32 factorial design

Abstract Context: Short residence time, poor bioavailability and poor permeability are the major problems for conventional eye drops treatment. Objective: The aim of this article is to develop, optimize and ex vivo–in vivo investigation of brimonidine tartrate in situ gel as compared to marketed eye drops for the treatment of glaucoma. Materials and methods: The effect of independent variables, namely concentrations of polymers, on various dependent variables like viscosity at physiological pH and in vitro drug release were studied by using 32 factorial design. Further the optimized formulation was characterized for ex vivo and in vivo study. Results and discussion: Experimental data demonstrated that optimized in situ gel formulation (F8) showed in vitro–ex vivo sustained release profile with polymer composites carbopol 974P and HPMC K4M. After 5 h of ex vivo transcorneal permeation study, the amount recovered from the corneal surface on the donor chamber 12.40% (124 ug) and the amount collected from the receptor chamber 76.8% (760 ug) of the initial dose 1 mg. The total amount recovered from the permeation experiment was 89.2%. Bioadhesive carbopol 974P and viscosity HPMC K4M composites optimized formulation (F 8) produce greater influence on the duration of drug action and improved intraocular pressure reduction activity as compared to marketed eye drop solution in in vivo study. Conclusion: The developed in situ gelling system as a promising ophthalmic formulation to prolong the drug lowering effect on the intraocular pressure.

[1]  P. Bandyopadhyay,et al.  Formulation of Protein- and Peptide-Based Parenteral Products , 2016, Parenteral Medications.

[2]  K. Avis Pharmaceutical Dosage Forms : Parenteral Medications , 2018 .

[3]  C. Kokare,et al.  Influence of hydroxypropylmethylcellulose and poloxamer composite on developed ophthalmic in situ gel: Ex vivo and in vivo characterization , 2016 .

[4]  Azza A. Hasan Design and in vitro characterization of small unilamellar niosomes as ophthalmic carrier of dorzolamide hydrochloride , 2014, Pharmaceutical development and technology.

[5]  Rakesh Kumar,et al.  Preparation and optimization of voriconazole microemulsion for ocular delivery. , 2014, Colloids and surfaces. B, Biointerfaces.

[6]  A. E. S. Abou El Ela,et al.  Formulation and evaluation of new long acting metoprolol tartrate ophthalmic gels , 2014, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[7]  M. Amaral,et al.  In situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations. , 2014, Drug discovery today.

[8]  C. Kokare,et al.  Formulation and in vitro evaluation of xanthan gum-based bilayered mucoadhesive buccal patches of zolmitriptan. , 2014, Carbohydrate polymers.

[9]  V. Pokharkar,et al.  Rheological investigation and its correlation with permeability coefficient of drug loaded carbopol gel: influence of absorption enhancers , 2013, Drug development and industrial pharmacy.

[10]  P. Pawar,et al.  Preparation and In Vitro/Ex Vivo Evaluation of Moxifloxacin-Loaded PLGA Nanosuspensions for Ophthalmic Application , 2013, Scientia pharmaceutica.

[11]  S. Pund,et al.  Ex vivo permeation characteristics of venlafaxine through sheep nasal mucosa. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  A. Arunachalam,et al.  Niosomes: A Novel Drug Delivery System , 2012 .

[13]  A. Mahmoud,et al.  Biodegradable Ocular Inserts for Sustained Delivery of Brimonidine Tartarate: Preparation and In Vitro/In Vivo Evaluation , 2011, AAPS PharmSciTech.

[14]  G. M. Gelfuso,et al.  Enhancing and sustaining the topical ocular delivery of fluconazole using chitosan solution and poloxamer/chitosan in situ forming gel. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[15]  Jin-Oh You,et al.  Bioresponsive matrices in drug delivery , 2010, Journal of biological engineering.

[16]  R. Charyulu,et al.  Preparation and Evaluation of Nano-vesicles of Brimonidine Tartrate as an Ocular Drug Delivery System , 2010, Journal of young pharmacists : JYP.

[17]  V. H. Sarmento,et al.  A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[18]  A. Mahmoud,et al.  Nanoemulsion as a Potential Ophthalmic Delivery System for Dorzolamide Hydrochloride , 2009, AAPS PharmSciTech.

[19]  Chi H. Lee,et al.  Thixotropic property in pharmaceutical formulations. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[20]  L. Ambrosio,et al.  A novel poloxamers/hyaluronic acid in situ forming hydrogel for drug delivery: rheological, mucoadhesive and in vitro release properties. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[21]  N. M. Zaki,et al.  Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[22]  F. Manvi,et al.  In situ-forming hydrogels for sustained ophthalmic drug delivery. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[23]  Jagdish Singh,et al.  Smart polymer based delivery systems for peptides and proteins. , 2007, Recent patents on drug delivery & formulation.

[24]  Chunjie Wu,et al.  Preparation and evaluation of a Carbopol/HPMC-based in situ gelling ophthalmic system for puerarin. , 2007, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[25]  L. Cantor Brimonidine in the treatment of glaucoma and ocular hypertension , 1997, Therapeutics and clinical risk management.

[26]  J. M. Marchetti,et al.  Sustained release of lidocaine from Poloxamer 407 gels. , 2005, International journal of pharmaceutics.

[27]  D. Attwood,et al.  In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. , 2001, International journal of pharmaceutics.

[28]  P. Amin,et al.  Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[29]  Hong-Ru Lin,et al.  Carbopol/pluronic phase change solutions for ophthalmic drug delivery. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[30]  N. Davies,et al.  Biopharmaceutical Considerations In Topical Ocular Drug Delivery , 2000, Clinical and experimental pharmacology & physiology.

[31]  S. Keipert,et al.  Physico-chemical, in vitro and in vivo characterisation of polymers for ocular use. , 2000, Die Pharmazie.

[32]  P. Hoyng,et al.  Pharmacological therapy for glaucoma: a review. , 2000, Drugs.

[33]  L. Silver Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group. , 2000, Survey of ophthalmology.

[34]  H. Sasaki,et al.  Delivery of drugs to the eye by topical application , 1996, Progress in Retinal and Eye Research.

[35]  Andreas Zimmer,et al.  Microspheres and nanoparticles used in ocular delivery systems , 1995 .

[36]  D. Meisner,et al.  Liposome ocular delivery systems , 1995 .

[37]  D. Craig,et al.  Rheological Evaluation of Polyacrylic Acid Hydrogels , 1995 .